Steven Cohen Syros Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$6.66 - $14.66 $4.38 Million - $9.65 Million	-657,986 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$8.69 - $14.47 $7.61 Million - $12.7 Million	-875,934 Reduced 57.1%	657,986 $5.82 Million
Q2 2020 Aug 14, 2020	SELL	$5.21 - $11.03 $3.86 Million - $8.17 Million	-741,080 Reduced 32.57%	1,533,920 $16.4 Million
Q1 2020 May 15, 2020	BUY	$4.46 - $9.2 $10.1 Million - $20.9 Million	2,275,000 New	2,275,000 $13.5 Million
Q1 2019 May 15, 2019	SELL	$5.51 - $9.59 $1.32 Million - $2.3 Million	-240,000 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$5.55 - $11.34 $877,799 - $1.79 Million	158,162 Added 193.26%	240,000 $1.34 Million
Q3 2018 Nov 14, 2018	SELL	$9.74 - $12.92 $827,490 - $1.1 Million	-84,958 Reduced 50.94%	81,838 $975,000
Q2 2018 Aug 14, 2018	BUY	$10.16 - $13.65 $1.69 Million - $2.28 Million	166,796 New	166,796 $1.7 Million

Ticker SYRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,236,200
Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.